Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Biodesix (BDSX) EBIAT (2019 - 2026)

Biodesix filings provide 8 years of EBIAT readings, the most recent being -$7.8 million for Q1 2026.

  • On a quarterly basis, EBIAT rose 29.8% to -$7.8 million in Q1 2026 year-over-year; TTM through Mar 2026 was -$32.0 million, a 20.93% increase, with the full-year FY2025 number at -$35.3 million, up 17.86% from a year prior.
  • EBIAT hit -$7.8 million in Q1 2026 for Biodesix, down from -$4.0 million in the prior quarter.
  • In the past five years, EBIAT ranged from a high of -$4.0 million in Q4 2025 to a low of -$20.3 million in Q4 2022.
  • Median EBIAT over the past 5 years was -$11.1 million (2025), compared with a mean of -$12.0 million.
  • Biggest five-year swings in EBIAT: tumbled 123.9% in 2022 and later skyrocketed 55.29% in 2023.
  • Biodesix's EBIAT stood at -$20.3 million in 2022, then skyrocketed by 55.29% to -$9.1 million in 2023, then grew by 9.26% to -$8.3 million in 2024, then soared by 51.76% to -$4.0 million in 2025, then plummeted by 95.8% to -$7.8 million in 2026.
  • The last three reported values for EBIAT were -$7.8 million (Q1 2026), -$4.0 million (Q4 2025), and -$8.7 million (Q3 2025) per Business Quant data.